Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-08-02
1999-04-06
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514255, 514256, 514291, 514312, 544238, 544333, 544405, 546 90, 546156, A61K 3147, A61K 3150, A61K 31505
Patent
active
058918787
ABSTRACT:
1-Alkyl-substituted-quinolone-3-carboxamides have therapeutic utility via inhibition of Phosphodiesterase IV esterase and/or Tumour Necrosis Factor activity. The compounds of the invention have the general formula (I): ##STR1## The compounds of the invention encompassed by formula (I) include enantiomers, diastereoisomers and mixtures, including racemic mixtures.
REFERENCES:
patent: 3524858 (1970-08-01), Kaminsky et al.
patent: 4621088 (1986-11-01), Laruelle et al.
patent: 4786644 (1988-11-01), Glamkowski et al.
Nicholson, C.D. et al, `Differential Modulation of Tissue Function and Therapeutic Potential of Selective Inhibitors of Cyclic Nucleotide Phosphodiesterase Isoenzymes`, Trends Pharm. Sci. 1991, 12(1) pages 19-27.
Valtin, H. et al, `Causes of the urinary Concentrating Defect in Mice with Nephrogenic Diabetes Insipidus`, Physiologia Bohemoslovaca, 1990, 39(1), pp. 103-111, abstract only.
Hall, I.P., `Isoenzyme Selective Phosphodiesterase Inhibitors: Potential Clinical Uses`, Brit. J. Clin. Pharm., 1993, 35(1), pp. 1-7.
Giembycz, M.A. et al, `Prospects for Selective Cyclic Nucleotide Phosphodiesterase Inhibitors in the Treatment of Bronchial Asthma`, Clin. Exp. Allergy, 1992, 22(3), pp. 337-344.
Weller, P.F. in Cecil Textbook of Medicine, edited by J.B. Wyngaarden et al, 19th ed. W.B. Saunders Co., 1992, pp. 965-967.
Cavalla, D., R. Frith (1995) "Phosphodiesterase IV Inhibitors: Structural Diversity and Therapeutic Potential in Asthma" Current Medicinal Chemistry 2:561-572.
Dent, G. M.A. Giembycz (1995) "Selective Phosphodiesterase Inhibitors int he Therapy of Asthma" Clinical Immunotherapeutics 3(6):423-437.
Lee, J.C. et al. (1995) "Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives" Circulatory Shock 44:97-103.
Nishikawa, Y. et al. (1989) "Synthesis and Antiallergic Activity of 4-dihydro-4-oxopyidine-3-carboxamides" Chem. Pharm. Bull 37(5):1256-1259.
Palfreyman, M.N. (1995) "Phosphodiesterase type IV inhibitors as antiflammatory agents" Drugs of the Future 20(8):793-804.
Schudt, C. et al, "Zardaverine: A Cyclic AMPP Specific PDE III/IV Inhibitor" Agents and Actions, Suppl., 1991, 34, pp. 379-402, abstract only.
Tramontana, J.M. et al, "Thalidomide Treatment Reduces Tumor Necrosis Factor Alpha Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis" Mol. Med. 1995, 1(4), pp. 384-397, abstract only.
Baxter Andrew Douglas
Beasley Steven Colin
Buckley George Martin
Dyke Hazel John
Haughan Alan Findlay
Chiroscience Limited
Raymond Richard L.
LandOfFree
Quinolones and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinolones and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolones and their therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371589